Featured Research

from universities, journals, and other organizations

Researchers Develop First Way To Immunize Against A Deadly Bacterium

Date:
March 31, 1999
Source:
University Of California San Francisco
Summary:
Laboratory researchers have developed a new way to cripple a virulent class of microbes that have become increasingly resistant to antibiotics and continue to kill hundreds of thousands of hospital patients every year.

Laboratory researchers have developed a new way to cripple avirulent class of microbes that have become increasinglyresistant to antibiotics and continue to kill hundreds ofthousands of hospital patients every year.

The discovery, based on experiments with laboratory mice,provides immunization against the Pseudomonas aeruginosabacterium, suggesting a fresh alternative to antibiotics inthe fight against the microbes responsible for mosthospital-acquired pneumonia deaths. The bacteria kill halfthe hospital patients they infect.

The new finding led by scientists at the University ofCalifornia San Francisco and the Medical College ofWisconsin is reported in the April issue of Nature Medicine.A commentary on the research and its significance appears inthe same issue.

Nationally, more than two billion dollars a year are spentcombating hospital pneumonia, a condition most oftencontracted by patients already under intensive care.

The Pseudomonas species targeted in the research is alsoresponsible for the untreatable lung inflammations whichdevastate the lives of half a million people with cysticfibrosis. In addition, it belongs to the same group ofgram-negative bacteria as E. coli, Salmonella, and themicrobe responsible for plague, all of which may becandidates for the same immunization strategy developed bythe scientific team.

"All these species utilize the same combination of proteinsto deliver deadly toxins to host cells," says JeanineWiener-Kronish, MD, professor of anesthesiology and medicineUC San Francisco and one of the senior authors on the NatureMedicine paper. "We have developed an antibody against oneof these proteins and shown that it blocks Pseudomonas frominjecting toxins into lung cells. This antibody may wellprovide immunization against these other bacteria speciestoo."

Senior author on the Nature Medicine paper is Dara W. Frank,PhD, professor of microbiology and molecular genetics at theMedical College of Wisconsin. The collaboration involvedseven scientists from the two institutions, combining basicresearch in critical patient care and bacterial genetics todevelop the antibody and demonstrate its ability to provideimmunity against the Pseudomonas bacterium. First author onthe paper is Teiji Sawa, MD, PhD, adjunct assistantprofessor of anesthesiology at UCSF.

The bacterium employs what is known as a type III secretorysystem to infect lung cells. A combination of at least 25bacterial proteins work in concert to allow the microbeaccess to penetrate the outer surface of the host cell andinject toxins into it. The toxins are particularly difficultfor the cell to defend against, Wiener-Kronish explained,because they wipe out the primary line of defense -- themacrophages which would normally engulf such invaders.

The research team developed antibodies to five of theproteins in the bacterium's toxin delivery system and testedthe ability of each to block the deadly process. One of thefive, an antibody to the bacterium's PcrV antigen, preventedthe invading microbe from destroying the lung cellmacrophages. As a result, the cells could mount a defenseagainst the bacteria and prevent delivery of the toxin.Most importantly, lung cells were protected, the researchersreport.

The scientists do not yet know the precise role of thebacterial protein they have blocked. They know it is neededfor successful delivery -- or translocation -- of the toxinfrom the bacterium to the lung tissue, and that it itself isnot a toxin, they report.

Immunization could be useful not only against thePseudomonas-induced pneumonia, but also against thedevastating lung inflammations suffered by people withcystic fibrosis, says Wiener-Kronish. These same virulentbacteria cause the chronic inflammations of cystic fibrosis,and sufferers are never able to clear their lungs of themicrobes. A systemic approach such as immunization may holdmore promise than efforts at control through antibiotics,she says.

The bacteria also cause sepsis, or infection of the blood,by passing from the lungs into the bloodstream, and thescientists hope that sepsis too may be controlled throughantibody therapy.

The research group is now working with InterMunePharmaceutical, Inc. to develop an antibody therapy and avaccine for use in clinical trials with patients. Thescientists are also seeking to better understand how thebacterial type III secretory system works, expecting thatfurther refinements in the immunization strategy might bepossible.

"We're still in the development stages, but we think thatstudying PcrV may well reveal significant information aboutthe process of intoxication by type III systems," said DaraFrank of the Medical College of Wisconsin.

Collaborating in the research and on the paper with Sawa,Frank and Wiener-Kronish were Maria Ohara, MD, and KiyoyasuKurahashi MD, both Fellows in anesthesiology and MichaelGropper, MD, PhD, assistant professor of anesthesiology, allat UCSF, and Timothy L. Yahr, PhD, a postdoctoral scientistat Dartmouth Medical School. The research was funded by theNational Institutes of Health and the Cystic FibrosisFoundation.


Story Source:

The above story is based on materials provided by University Of California San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University Of California San Francisco. "Researchers Develop First Way To Immunize Against A Deadly Bacterium." ScienceDaily. ScienceDaily, 31 March 1999. <www.sciencedaily.com/releases/1999/03/990331063752.htm>.
University Of California San Francisco. (1999, March 31). Researchers Develop First Way To Immunize Against A Deadly Bacterium. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/1999/03/990331063752.htm
University Of California San Francisco. "Researchers Develop First Way To Immunize Against A Deadly Bacterium." ScienceDaily. www.sciencedaily.com/releases/1999/03/990331063752.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins